Core Viewpoint - The approval of Chloride Dihydropyridine Injection by the National Medical Products Administration of China represents a significant advancement for the company in the treatment of hypertension, particularly for patients who cannot take oral medications [1] Group 1: Product Details - The product is a dihydropyridine calcium channel blocker, classified as a rapid-acting intravenous antihypertensive drug [1] - It is specifically designed for patients who are unsuitable for oral medication or have poor expected outcomes from oral treatments [1] Group 2: Advantages - The injection has notable advantages over commonly used clinical medications, including faster onset of action and the ability to achieve rapid, real-time, and precise blood pressure control [1] - It is particularly suitable for patients with liver and kidney dysfunction, as dosage adjustments are not required during treatment [1] - The product does not require dilution or preparation, which significantly benefits patients at risk of fluid overload [1] Group 3: Market Impact - The approval will enhance the company's product pipeline in the cardiovascular disease treatment sector, increasing its competitiveness in this field [1] - It is expected to address the clinical demand gap for emergency hypertension medications [1]
石药集团(01093.HK)氯维地平乳状注射液获药品注册批件